Alpha 2.0
Login Register
» Authors » Samuel L M Arnold

Samuel L M Arnold

Explore the profile of Samuel L M Arnold including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 40
Citations 490
Followers 0
Related Specialties
Pharmacology
Infectious Diseases
Parasitology
Top 10 Co-Authors
Wesley C Van Voorhis
Matthew A Hulverson
Ryan Choi
Kayode K Ojo
Lynn K Barrett
Grant R Whitman
Dustin J Maly
Molly C McCloskey
Erkang Fan
Andrew Hemphill
Published In
J Infect Dis
Antimicrob Agents Chemother
Sci Rep
Int J Parasitol Drugs Drug Resist
ACS Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Potential and challenges in application of physiologically based pharmacokinetic modeling in predicting diarrheal disease impact on oral drug pharmacokinetics
Zhang C, Arnold S
Drug Metab Dispos . 2025 Jan; 53(1):100014. PMID: 39884815
Physiologically based pharmacokinetic (PBPK) modeling is a physiologically relevant approach that integrates drug-specific and system parameters to generate pharmacokinetic predictions for target populations. It has gained immense popularity for drug-drug...
2.
Treatment with BKI-1748 after systemic dissemination in experimentally infected pregnant sheep improves fetal and lamb mortality and morbidity and prevents congenital infection
Sanchez-Sanchez R, Huertas-Lopez A, Largo-de la Torre A, Ferre I, Dini F, Re M, et al.
Antimicrob Agents Chemother . 2025 Jan; 69(2):e0144824. PMID: 39745365
Drug development for congenital toxoplasmosis is challenging since first-line therapy has a high rate of adverse effects and exhibits suboptimal efficacy. Bumped kinase inhibitors (BKIs), targeting protein kinases with small...
3.
Pharmacokinetics of tebipenem pivoxil used in children suffering from shigellosis: a pilot study in Bangladesh
Nuzhat S, Islam M, Bashar S, Das S, Amin R, Qadri F, et al.
Sci Rep . 2024 Dec; 14(1):31965. PMID: 39738375
With increasing antibiotic resistance in gram-negative bacteria, including those causing Shigellosis, evidence of safety and pharmacokinetics data on new oral antibiotics is crucial. We aimed to investigate the safety and...
4.
Antibiotic use prior to attending a large diarrheal disease hospital among preschool children suffering from bloody or non-bloody diarrhea: A cross-sectional study conducted in Bangladesh
Bashar S, Islam M, Nuzhat S, Amin R, Rahman M, Pavlinac P, et al.
PLoS One . 2024 Nov; 19(11):e0314325. PMID: 39591443
Background: Among diarrheal children, injudicious use of antibiotics is a major public health concern particularly in low- and middle-income countries. There are evidence-based guidelines by the World Health Organization (WHO)...
5.
Efficacy of the bumped kinase inhibitor BKI-1708 against the cyst-forming apicomplexan parasites Toxoplasma gondii and Neospora caninum in vitro and in experimentally infected mice
de Sousa M, Imhof D, Hanggeli K, Choi R, Hulverson M, Arnold S, et al.
Int J Parasitol Drugs Drug Resist . 2024 Jun; 25:100553. PMID: 38917582
Toxoplasma gondii and Neospora caninum are major worldwide morbidity-causing pathogens. Bumped kinase inhibitors (BKIs) are a compound class that has been optimized to target the apicomplexan calcium-dependent protein kinase 1...
6.
A Compound That Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer
Uo T, Ojo K, Sprenger C, Epilepsia K, Perera B, Damodarasamy M, et al.
Mol Cancer Ther . 2024 Mar; 23(7):973-994. PMID: 38507737
Metastatic castration-resistant prostate cancer remains incurable regardless of recent therapeutic advances. Prostate cancer tumors display highly glycolytic phenotypes as the cancer progresses. Nonspecific inhibitors of glycolysis have not been utilized...
7.
Clofazimine pharmacokinetics in HIV-infected adults with diarrhea: Implications of diarrheal disease on absorption of orally administered therapeutics
Zhang C, Conrad T, Hermann D, Gordon M, Houpt E, Iroh Tam P, et al.
CPT Pharmacometrics Syst Pharmacol . 2024 Jan; 13(3):410-423. PMID: 38164114
Oral drug absorption kinetics are usually established in populations with a properly functioning gastrointestinal tract. However, many diseases and therapeutics can alter gastrointestinal physiology and cause diarrhea. The extent of...
8.
An Early Treatment With BKI-1748 Exhibits Full Protection Against Abortion and Congenital Infection in Sheep Experimentally Infected With Toxoplasma gondii
Sanchez-Sanchez R, Imhof D, Hecker Y, Ferre I, Re M, Moreno-Gonzalo J, et al.
J Infect Dis . 2023 Oct; 229(2):558-566. PMID: 37889572
Congenital toxoplasmosis in humans and in other mammalian species, such as small ruminants, is a well-known cause of abortion and fetal malformations. The calcium-dependent protein kinase 1 (CDPK1) inhibitor BKI-1748...
9.
A Compound that Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer
Uo T, Ojo K, Sprenger C, Epilepsia K, Perera B, Damodarasamy M, et al.
bioRxiv . 2023 Jul; PMID: 37461469
Purpose: Metastatic castration-resistant prostate cancer remains incurable regardless of recent therapeutic advances. Prostate cancer tumors display highly glycolytic phenotypes as the cancer progresses. Non-specific inhibitors of glycolysis have not been...
10.
A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations
Steinbronn C, Chhonker Y, Stewart J, Leingang H, Heller K, Krows M, et al.
Clin Transl Sci . 2023 Apr; 16(7):1243-1257. PMID: 37118968
Hydroxychloroquine (HCQ) is Food and Drug Administration (FDA)-approved for malaria, systemic and chronic discoid lupus erythematosus, and rheumatoid arthritis. Because HCQ has a proposed multimodal mechanism of action and a...